Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical Limited announced promising Phase III clinical trial results for Anlotinib Hydrochloride Capsules in treating advanced renal cell carcinoma, with significantly improved median progression-free survival and objective remission rates compared to the control drug. The new treatment, which is undergoing regulatory review, could potentially become a new standard for first-line therapy, addressing the high incidence and mortality rates of the disease in China.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
